60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
Go back to 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis| (NASDAQ: SXTP) | Delayed: 1.69 +0.05 (3.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.64 | 52 Week High | $ | |||
| Open | $1.63 | 52 Week Low | $ | |||
| Day High | $1.78 | P/E | N/A | |||
| Day Low | $1.63 | EPS | $ | |||
| Volume | 78,344 | |||||
| (NASDAQ: SXTPW) | Delayed: 0.04 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.04 | 52 Week High | $ | |||
| Open | $0.04 | 52 Week Low | $ | |||
| Day High | $0.04 | P/E | N/A | |||
| Day Low | $0.04 | EPS | $ | |||
| Volume | 2,574 | |||||
